Celcuity (CELC) Liabilities and Shareholders Equity (2016 - 2025)
Celcuity (CELC) reported Liabilities and Shareholders Equity of $466.6 million for Q4 2025, up 90.34% on a YoY basis from $245.1 million in Q4 2024, and down 1.98% quarter-over-quarter from $476.0 million in Q3 2025.
Celcuity (CELC) Liabilities and Shareholders Equity (2016 - 2025) Analysis & Trends
Celcuity has reported Liabilities and Shareholders Equity for 10 years, with the latest figure at $466.6 million in Q4 2025.
- For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 90.34% year-over-year to $466.6 million; the trailing twelve-month figure through Dec 2025 stood at $1.3 billion (up 34.58% YoY), and the FY2025 full-year result was $466.6 million, up 90.34% from the prior year.
- Liabilities and Shareholders Equity for Q4 2025 stood at $466.6 million, down from $476.0 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $476.0 million in Q3 2025, with the low at $36.4 million in Q1 2021.
- Historically, Liabilities and Shareholders Equity has averaged $182.3 million across 5 years, with a median of $170.3 million in 2022.
- Annual changes were most pronounced in 2021 — Liabilities and Shareholders Equity soared 563.02% — and 2025, when it slumped 37.24%.
- Celcuity's Liabilities and Shareholders Equity stood at $85.9 million in 2021, then jumped by 104.52% to $175.7 million in 2022, then gained by 8.83% to $191.2 million in 2023, then grew by 28.19% to $245.1 million in 2024, then jumped by 90.34% to $466.6 million in 2025.
- The last three Liabilities and Shareholders Equity figures came in at $466.6 million (Q4 2025), $476.0 million (Q3 2025), and $183.6 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 37.37 Mn |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | 811.27 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 14.93 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 1.73 Bn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 33.89 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | 23.64 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 12.81 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 26.48 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 640.56 Mn |
| 10 | Celcuity | 4.14 Bn | 3.42 Bn | - | 466.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 466.56 Mn |
| Sep 30, 2025 | 476.00 Mn |
| Jun 30, 2025 | 183.59 Mn |
| Mar 31, 2025 | 218.13 Mn |
| Dec 31, 2024 | 245.12 Mn |
| Sep 30, 2024 | 273.04 Mn |
| Jun 30, 2024 | 292.54 Mn |
| Mar 31, 2024 | 188.18 Mn |
| Dec 31, 2023 | 191.22 Mn |
| Sep 30, 2023 | 142.38 Mn |
| Jun 30, 2023 | 153.52 Mn |
| Mar 31, 2023 | 164.87 Mn |
| Dec 31, 2022 | 175.70 Mn |
| Sep 30, 2022 | 65.29 Mn |
| Jun 30, 2022 | 72.35 Mn |
| Mar 31, 2022 | 79.93 Mn |
| Dec 31, 2021 | 85.91 Mn |
| Sep 30, 2021 | 91.84 Mn |
| Jun 30, 2021 | 42.81 Mn |
| Mar 31, 2021 | 36.37 Mn |